Pearson Nurse's Drug Guide 2016
Description:
Pearson Nurse’s Drug Guide 2016 is ideal for courses in nursing curricula covering drugs and/or drug administration. It also serves as a useful reference for nursing professionals.
The information nurses need for safe, effective drug administration in any setting
With over 400 updates, the new 2016 edition of the Pearson Nurse’s Drug Guide provides safe, effective, current, and accurate drug information in a quickly accessible format. Comprehensive and complete, it lists all drugs alphabetically by generic names for quick reference, with an index listing both generic and trade names. It presents important clinical information for hundreds of drugs, with adverse reactions, interactions, side effects, and impacts on lab results.
This new edition includes clearly delineated black box warnings, 23 monographs for new drugs recently approved by the Food and Drug Administration (FDA), and a new appendix on Topical Antifungal Medications. IV administration information has been updated regarding adults as well as children. These revisions include subheadings for IV preparation and administration of IV medications for children, which add to the ease of locating appropriate information by age.
Best prices to buy, sell, or rent ISBN 9780134070643
Frequently Asked Questions about Pearson Nurse's Drug Guide 2016
The price for the book starts from $11.10 on Amazon and is available from 11 sellers at the moment.
If you’re interested in selling back the Pearson Nurse's Drug Guide 2016 book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Pearson Nurse's Drug Guide 2016 book, the best buyback offer comes from and is $ for the book in good condition.
The Pearson Nurse's Drug Guide 2016 book is in very low demand now as the rank for the book is 3,048,884 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.
Not enough insights yet.